Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In


Treatment of Hepatocellular Carcinoma

Hepatocellular carcinoma is the third leading cause of cancer-related death worldwide. We review the treatment options and recommendations for patients with HCC.
CME credit is no longer available for this conference.

Course Authors

Brian C. Davis, M.D., and Amit G. Singal, M.D., M.S.

Dr. Davis Is Resident Physician and Dr. Singal is Associate Professor, Medical Director of Liver Tumor Program, Department of Internal Medicine, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX.

Within the past 12 months, Dr Davis has no conflicts of interest relevant to this activity. Dr. Singal is on the speaker’s bureau for Bayer, consulted for Bayer and Wako Diagnostics and has received research support from Gilead.

Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose relevant to this activity.

Estimated course time: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • List and discuss effective methods for prevention and early detection of HCC in patients with cirrhosis;

  • Recommend treatment options for patients with cirrhosis and HCC at all stages – early stage, intermediate stage, advanced stage, and terminal stage;

  • Integrate the role of multidisciplinary care for treatment of patients with HCC.



The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.


Please click below to accept the terms of this CME activity

Courses You Might Like

GI Manifestations of Covid-19

The coronavirus disease-2019 (COVID-19) is more than a respiratory condition. We look at its GI manifestations.
Authors: Max Schmulson, M.D., R.F.F.
Estimated Time: 1 Hour

Pancreatic Adenocarcinoma

Pancreatic cancer continues to far outpace its incidence rate with respect to mortality.
Authors: Parvin Peddi, M.D., and Andrea Wang-Gillam, M.D.
Estimated Time: 1 Hour

The Indigenous Gastrointestinal Microbiota in Health and Disease

The microbiota can play key roles both in maintenance of health as well as the pathogenesis of disease within the gastrointestinal tract.
Authors: John Y. Kao, M.D., Nirmal Kaur, M.D., and Vincent B. Young M.D., Ph.D.
Estimated Time: 1 Hour

Liver Fibrosis: New Mechanisms, New Treatments, and Why They Matter

Liver fibrosis, like pathological fibrosis in other organs, has been termed "wound healing gone bad."
Authors: Rebecca G. Wells, M.D.
Estimated Time: 1 Hour

Chronic Pancreatitis: Diagnosis and Management

The most common etiology of chronic pancreatitis is alcohol abuse.
Authors: Stephen Pandol, M.D., and Hartley Cohen, M.D.
Estimated Time: 1 Hour

Acute Pancreatitis: Diagnosis and Management

Acute pancreatitis is a disorder primarily of the exocrine pancreas .
Authors: Stephen J. Pandol M.D.
Estimated Time: 1 Hour